MYL9 and cancer: Our results revealed that genes in the downregulated gene set (e.g., MYL9, ABCG2, SORBS1, NRG1, CRYAB) were significantly suppressed in more than 17 cancer types that share the common outcome of losing tumor-suppressive functions, thereby promoting proliferation, invasion, metastasis, and therapy resistance in various cancers (including SCTs).